BACKGROUND: We retrospectively investigated (18)F-FDG uptake by the primary breast tumor as a predictor for relapse and survival. PATIENTS AND METHODS: We studied 203 patients with cT1-T3N0 breast cancer. Standardized uptake value (SUVmax), was measured on the primary tumor. After a median follow-up of 68 months (range 22-80), the relation between SUVmax and tumor factors, disease free-survival (DFS) and overall survival (OS) was investigated. RESULTS: In the PET-positive patients, the median FDG uptake by the tumor was 4.7. FDG uptake was significantly related to tumor size, number of involved axillary nodes, grade, negative ER, high Ki-67 and HER2 overexpression. No distant metastases or deaths occurred in the PET-negative group. Five-year DFS was 97% and 83%, respectively in the PET-negative and PET-positive groups (P = 0.096). At univariate analysis, DFS was significantly lower in patients with SUVmax >4.7 compared to the patients with negative PET (P = 0.042), but not to the patients with SUVmax ≤4.7 (P = 0.106). At multivariable analysis, among PET-positive patients, SUVmax was not an independent prognostic factor for DFS (HR(>4.7 vs ≤4.7): 1.02 (95% CI 0.45-2.31)). Five-year OS was 100% and 93%, respectively, in the PET-negative and PET-positive groups (P = 0.126). CONCLUSION: FDG uptake by the primary lesion was significantly associated with several prognostic variables, but it was not an independent prognostic factor.
BACKGROUND: We retrospectively investigated (18)F-FDG uptake by the primary breast tumor as a predictor for relapse and survival. PATIENTS AND METHODS: We studied 203 patients with cT1-T3N0 breast cancer. Standardized uptake value (SUVmax), was measured on the primary tumor. After a median follow-up of 68 months (range 22-80), the relation between SUVmax and tumor factors, disease free-survival (DFS) and overall survival (OS) was investigated. RESULTS: In the PET-positive patients, the median FDG uptake by the tumor was 4.7. FDG uptake was significantly related to tumor size, number of involved axillary nodes, grade, negative ER, high Ki-67 and HER2 overexpression. No distant metastases or deaths occurred in the PET-negative group. Five-year DFS was 97% and 83%, respectively in the PET-negative and PET-positive groups (P = 0.096). At univariate analysis, DFS was significantly lower in patients with SUVmax >4.7 compared to the patients with negative PET (P = 0.042), but not to the patients with SUVmax ≤4.7 (P = 0.106). At multivariable analysis, among PET-positive patients, SUVmax was not an independent prognostic factor for DFS (HR(>4.7 vs ≤4.7): 1.02 (95% CI 0.45-2.31)). Five-year OS was 100% and 93%, respectively, in the PET-negative and PET-positive groups (P = 0.126). CONCLUSION: FDG uptake by the primary lesion was significantly associated with several prognostic variables, but it was not an independent prognostic factor.
Authors: Gamze Uğurluer; Sinan Yavuz; Züleyha Çalıkuşu; Ertuğrul Seyrek; Mustafa Kibar; Meltem Serin; Canan Ersöz; Orhan Demircan Journal: J Breast Health Date: 2016-07-01
Authors: Heinrich Magometschnigg; Katja Pinker; Thomas Helbich; Anita Brandstetter; Margaretha Rudas; Thomas Nakuz; Pascal Baltzer; Wolfgang Wadsak; Marcus Hacker; Michael Weber; Peter Dubsky; Martin Filipits Journal: Mol Imaging Biol Date: 2019-10 Impact factor: 3.488
Authors: Mariarosaria Incoronato; Anna Maria Grimaldi; Carlo Cavaliere; Marianna Inglese; Peppino Mirabelli; Serena Monti; Umberto Ferbo; Emanuele Nicolai; Andrea Soricelli; Onofrio Antonio Catalano; Marco Aiello; Marco Salvatore Journal: Eur J Nucl Med Mol Imaging Date: 2018-04-25 Impact factor: 9.236
Authors: Sung Gwe Ahn; Jong Tae Park; Hak Min Lee; Hak Woo Lee; Tae Joo Jeon; Kyunghwa Han; Seung Ah Lee; Seung Myung Dong; Young Hoon Ryu; Eun Ju Son; Joon Jeong Journal: Breast Cancer Res Date: 2014 Impact factor: 6.466
Authors: Onofrio Antonio Catalano; Gary Lloyd Horn; Alberto Signore; Carlo Iannace; Maria Lepore; Mark Vangel; Angelo Luongo; Marco Catalano; Constance Lehman; Marco Salvatore; Andrea Soricelli; Ciprian Catana; Umar Mahmood; Bruce Robert Rosen Journal: Br J Cancer Date: 2017-02-16 Impact factor: 7.640